Department of Nephrology, Affiliated Hospital of Youjiang Medical University for Nationalities, No.18 Zhongshan Road, Baise, 533000, Guangxi, China.
College of Biological Science and Engineering, Fuzhou University, Fuzhou, 350108, China.
BMC Cancer. 2022 Nov 17;22(1):1184. doi: 10.1186/s12885-022-10302-2.
An increasing number of studies have demonstrated that CX3CL1 is involved in the development of tumors and may thus be considered a new potential therapeutic target for them. However, the function of CX3CL1 in clear cell renal cell carcinoma (ccRCC) remains poorly defined.
The pan-cancer expression pattern and prognostic value of CX3CL1 were evaluated in this study. Moreover, the relationship of CX3CL1 expression with the tumor microenvironment, especially the tumor immune microenvironment, was analyzed. Our analyses employed public repository data. Additionally, we generated stable CX3CL1-overexpressing 786-O cells to determine the role of CX3CL1 in vitro via cell viability and transwell assays. A xenograft tumor model was used to determine the role of CX3CL1 in vivo. The association between CX3CL1 and ferroptosis sensitivity of tumor cells was assessed using Ferrostatin-1.
Our findings indicated the involvement of CX3CL1 in the occurrence and development of ccRCC by acting as a tumor suppressor. We also found that ccRCC patients with high CX3CL1 expression showed better clinical outcomes than those with low CX3CL1 expression. The findings of our epigenetic study suggested that the expression of CX3CL1 in ccRCC is correlated with its DNA methylation level. Furthermore, the CX3CL1 expression level was closely related to the infiltration level of CD8 T cells into the tumor microenvironment (TME). CX3CL1 showed different predictive values in different immunotherapy cohorts. Finally, CX3CL1 overexpression inhibited tumor cell proliferation and metastasis and promoted tumor ferroptosis sensitivity in ccRCC.
This study revealed the role of CX3CL1 as a tumor suppressor in ccRCC. Our findings indicated that CX3CL1 plays a crucial role in regulating the ccRCC TME and is a potential predictor of immunotherapy outcomes in ccRCC. We also found that CX3CL1 can promote ferroptosis sensitivity in ccRCC cells.
越来越多的研究表明,CX3CL1 参与肿瘤的发生发展,因此可被视为肿瘤的一个新的潜在治疗靶点。然而,CX3CL1 在透明细胞肾细胞癌(ccRCC)中的作用仍不清楚。
本研究评估了 CX3CL1 在泛癌中的表达模式和预后价值。此外,还分析了 CX3CL1 表达与肿瘤微环境(尤其是肿瘤免疫微环境)的关系。我们的分析使用了公共存储库的数据。此外,我们还通过细胞活力和 Transwell 分析在体外生成稳定过表达 CX3CL1 的 786-O 细胞,以确定 CX3CL1 的作用。使用异种移植肿瘤模型在体内确定 CX3CL1 的作用。使用 Ferrostatin-1 评估 CX3CL1 与肿瘤细胞铁死亡敏感性的关系。
我们的研究结果表明,CX3CL1 通过作为肿瘤抑制因子参与 ccRCC 的发生和发展。我们还发现,CX3CL1 高表达的 ccRCC 患者的临床结局优于 CX3CL1 低表达的患者。我们的表观遗传学研究结果表明,ccRCC 中 CX3CL1 的表达与其 DNA 甲基化水平相关。此外,CX3CL1 的表达水平与 CD8 T 细胞浸润肿瘤微环境(TME)的水平密切相关。CX3CL1 在不同的免疫治疗队列中具有不同的预测价值。最后,CX3CL1 过表达抑制 ccRCC 肿瘤细胞的增殖和转移,并促进肿瘤的铁死亡敏感性。
本研究揭示了 CX3CL1 作为 ccRCC 肿瘤抑制因子的作用。我们的研究结果表明,CX3CL1 在调节 ccRCC TME 中起着关键作用,是 ccRCC 免疫治疗结果的潜在预测因子。我们还发现,CX3CL1 可以促进 ccRCC 细胞的铁死亡敏感性。